Itacitinib
- Generic Name
- Itacitinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23F4N9O
- CAS Number
- 1334298-90-6
- Unique Ingredient Identifier
- 19J3781LPM
- Background
Itacitinib has been used in trials studying the treatment of Melanoma, Carcinoma, Metastatic Cancer, Endometrial Cancer, and B-cell Malignancies, among others.
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-23
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 88
- Registration Number
- NCT02018861
- Locations
- 🇺🇸
Greenville Health System Cancer Institute, Greenville, South Carolina, United States
🇺🇸Nyu Langone Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
🇺🇸University Hospitals Case Medical Center, Cleveland, Ohio, United States
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 55
- Registration Number
- NCT01858883
A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 50
- Registration Number
- NCT01634087
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
- First Posted Date
- 2012-07-04
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 87
- Registration Number
- NCT01633372
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇨🇦St. Paul's Hospital, Vancouver, British Columbia, Canada
A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis
- First Posted Date
- 2012-06-22
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 106
- Registration Number
- NCT01626573
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath